Accelerated Phase Chronic Myelogenous Leukemia (CML) (DBCOND0121922)

Identifiers

Synonyms

Accelerated phase chronic myologenic leukaemia / Chronic Myelogenous Leukemia, Accelerated Phase / Chronic Myeloid Leukemia - Accelerated Phase / Accelerated phase chronic myologenic leukemia / Accelerated Phase Chronic Myelogenous Leukemia / Accelerated Phase Chronic Myeloid Leukemia / Leukemia, Myeloid, Accelerated-Phase / Leukemia, Myeloid, Accelerated Phase / Accelerated phase chronic myeloid leukemia (disorder) / Chronic myeloid leukaemia / Leukemia myelocytic chronic / Leukaemia myelocytic chronic / Chronic granulocytic leukaemia / Chronic myelogenous leukaemia / Myeloid leukemia, chronic / Chronic myelogenous leukemia / Chronic granulocytic leukemia / Myeloid leukaemia, chronic / CML / Chronic myelocytic leukaemia / Chronic myelocytic leukemia / Chronic myeloid leukemia / Leukaemias chronic myeloid / Chronic myeloid leukemia, BCR/ABL-positive / Chronic myeloid leukemia (disorder) / Chronic myeloid leukemia (morphologic abnormality) / Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Bosutinib	An antineoplastic agent used for the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adults with inadequate clinical response to other treatments.	Tyrosine-protein kinase ABL1target Tyrosine-protein kinase Lyntarget Proto-oncogene tyrosine-protein kinase Srctarget ATP-dependent translocase ABCB1transporter Cytochrome P450 3A4enzyme Dual specificity mitogen-activated protein kinase kinase 1target Dual specificity mitogen-activated protein kinase kinase 2target Mitogen-activated protein kinase kinase kinase 2target Calcium/calmodulin-dependent protein kinase type II subunit gammatarget Cytochrome P450 2C8enzyme Tyrosine-protein kinase Fgrtarget Tyrosine-protein kinase HCKtarget Tyrosine-protein kinase Tectarget STE20-like serine/threonine-protein kinasetarget
Dasatinib	A tyrosine kinase inhibitor used for the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia.	Tyrosine-protein kinase ABL1target Tyrosine-protein kinase ABL2target Proto-oncogene tyrosine-protein kinase Srctarget Tyrosine-protein kinase Fyntarget Tyrosine-protein kinase Lcktarget Tyrosine-protein kinase Yestarget Mast/stem cell growth factor receptor Kittarget Platelet-derived growth factor receptor betatarget Ephrin type-A receptor 2target Signal transducer and activator of transcription 5Btarget Cytochrome P450 3A4enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Cytochrome P450 1A1enzyme Cytochrome P450 1A2enzyme Cytochrome P450 1B1enzyme Cytochrome P450 3A5enzyme Flavin-containing monooxygenase 3enzyme Tyrosine-protein kinase BTKtarget Nuclear receptor subfamily 4 group A member 3target Breakpoint cluster region proteintarget Tyrosine-protein kinase CSKtarget Ephrin type-A receptor 5target Ephrin type-B receptor 4target Tyrosine-protein kinase Fgrtarget Tyrosine-protein kinase FRKtarget Heat shock cognate 71 kDa proteintarget Tyrosine-protein kinase Lyntarget Mitogen-activated protein kinase kinase kinase 20target Mitogen-activated protein kinase 14target Amidophosphoribosyltransferasetarget
Imatinib	A tyrosine kinase inhibitor used to treat a number of leukemias, myelodysplastic/myeloproliferative disease, systemic mastocytosis, hypereosinophilic syndrome, dermatofibrosarcoma protuberans, and gastrointestinal stromal tumors.	Platelet-derived growth factor receptor betatarget Tyrosine-protein kinase ABL1target Mast/stem cell growth factor receptor Kittarget Proto-oncogene tyrosine-protein kinase receptor Rettarget High affinity nerve growth factor receptortarget Macrophage colony-stimulating factor 1 receptortarget Platelet-derived growth factor receptor alphatarget Epithelial discoidin domain-containing receptor 1target Cytochrome P450 3A4enzyme Breakpoint cluster region proteintarget Cytochrome P450 1A2enzyme Cytochrome P450 2D6enzyme Cytochrome P450 2C9enzyme Cytochrome P450 2C19enzyme Cytochrome P450 3A5enzyme Cytochrome P450 3A7enzyme Solute carrier family 22 member 1transporter ATP-dependent translocase ABCB1transporter Solute carrier family 22 member 2transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Phospholipid-transporting ATPase ABCA3transporter Albumincarrier Alpha-1-acid glycoprotein 1carrier Bile salt export pumptransporter Cytochrome P450 2C8enzyme ATP-binding cassette sub-family C member 2transporter Multidrug resistance-associated protein 1transporter Organic cation/carnitine transporter 2transporter Solute carrier organic anion transporter family member 1B3transporter ATP-binding cassette sub-family C member 4transporter Solute carrier organic anion transporter family member 1A2transporter Discoidin domain-containing receptor 2target Induced myeloid leukemia cell differentiation protein Mcl-1target
Nilotinib	A kinase inhibitor used for the chronic phase treatment of Chronic Myeloid Leukemia (CML) that is Philadelphia chromosome positive and for the treatment of CML that is resistant to therapy containing imatinib.	Tyrosine-protein kinase ABL1target Mast/stem cell growth factor receptor Kittarget Cytochrome P450 2D6enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2C9enzyme Cytochrome P450 3A4enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter UDP-glucuronosyltransferase 1A1transporter Cytochrome P450 2B6enzyme Solute carrier organic anion transporter family member 1B1transporter
Ponatinib	A kinase inhibitor used to treat patients with various types of chronic myeloid leukemia (CML).	Tyrosine-protein kinase ABL1target Breakpoint cluster region proteintarget Mast/stem cell growth factor receptor Kittarget Proto-oncogene tyrosine-protein kinase receptor Rettarget Angiopoietin-1 receptortarget Receptor-type tyrosine-protein kinase FLT3target Cytochrome P450 3A4enzyme Cytochrome P450 2C8enzyme Cytochrome P450 2D6enzyme Cytochrome P450 3A5enzyme ATP-dependent translocase ABCB1transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter Fibroblast growth factor receptor 1target Fibroblast growth factor receptor 2target Fibroblast growth factor receptor 3target Fibroblast growth factor receptor 4target Tyrosine-protein kinase Lcktarget Proto-oncogene tyrosine-protein kinase Srctarget Tyrosine-protein kinase Lyntarget Vascular endothelial growth factor receptor 2target Platelet-derived growth factor receptor alphatarget

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT03842696	Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation	Cyclophosphamide Cyclosporine Methotrexate Mycophenolate mofetil Tacrolimus Vorinostat	prevention	1 / 2	recruiting
NCT05794880	MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing	No drug interventions	treatment	Not Available	recruiting
NCT05322850	Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)	No drug interventions	treatment	1 / 2	recruiting
NCT00123487	Advanced Chronic Myelogenous Leukemia (CML) - Follow On: Study of BMS-354825 in Subjects With CML	Dasatinib	treatment	3	completed
NCT05376852	Decitabine and HQP1351-based Chemotherapy Regimen for the Treatment Advanced CML	Decitabine HQP1351	treatment	2	recruiting
NCT03883100	A Pivotal Study of HQP1351 in Patients of Chronic Myeloid Leukemia in Accelerated Phase With T315I Mutation	HQP1351	treatment	2	active_not_recruiting
NCT00114959	Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)	Imatinib Omacetaxine mepesuccinate	treatment	2	terminated
NCT01761695	Chronic Myelod Leukemia Registry at Asan Medical Center	No drug interventions	Not Available	Not Available	terminated
NCT00489203	Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer	Beclomethasone dipropionate Methotrexate Tacrolimus	supportive_care	2	completed
NCT01233921	Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer	Palifermin	supportive_care	Not Available	completed
NCT04258943	Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia	Bosutinib	treatment	1 / 2	active_not_recruiting
NCT00316953	Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate	Dasatinib	treatment	1	completed
NCT00890747	Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy	Sunitinib	treatment	1	completed
NCT01177371	High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma	Busulfan Cyclophosphamide Cyclosporine Methotrexate Methylprednisolone Methylprednisolone hemisuccinate	treatment	2	completed
NCT01558778	Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	Not Available	withdrawn
NCT00101088	Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia	Imatinib Menthol Temsirolimus	treatment	1	terminated
NCT03647215	CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey	No drug interventions	Not Available	Not Available	completed
NCT00025415	Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction	Imatinib	treatment	1	completed
NCT00005799	Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer	Cyclosporine Fludarabine Mycophenolate mofetil Therapeutic allogeneic lymphocytes	treatment	Not Available	completed
NCT00004918	Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome	Incomplete Freund's adjuvant PR1 leukemia peptide vaccine Sargramostim	treatment	1 / 2	completed
NCT01426334	Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate	Cyclosporine Dasatinib	treatment	1	terminated
NCT01839916	Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Therapeutic allogeneic lymphocytes	treatment	2	completed
NCT00078858	Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1 / 2	completed
NCT01529827	Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Fludarabine Melphalan Methotrexate Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT01199562	Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant	Foscarnet Ganciclovir Valganciclovir	Not Available	Not Available	completed
NCT01159067	Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload	Deferasirox	supportive_care	2	terminated
NCT00049504	Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00077181	3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies	Cytarabine Triapine	treatment	1	completed
NCT00408681	Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant	Lithium carbonate	supportive_care	Not Available	completed
NCT00098423	Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes	Cytarabine Tanespimycin	treatment	1	completed
NCT00702403	Nilotinib and Imatinib Mesylate After Donor Stem Cell Transplant in Treating Patients With ALL or CML	Imatinib Nilotinib	treatment	1 / 2	completed
NCT01044745	Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Cyclophosphamide Fludarabine Mycophenolate mofetil Rituximab Tacrolimus	treatment	2	terminated
NCT00052598	Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant	Aldesleukin Therapeutic allogeneic lymphocytes	treatment	1 / 2	terminated
NCT00343798	A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies	Cyclophosphamide Cyclosporine Fludarabine Mycophenolate mofetil	treatment	1	completed
NCT00357305	Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders	Cytarabine Etoposide Vorinostat	treatment	1	completed
NCT00799461	Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications	No drug interventions	supportive_care	3	completed
NCT00089011	Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer	Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	completed
NCT00112593	Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer	Cyclosporine Fludarabine Mycophenolate mofetil	treatment	Not Available	completed
NCT00856388	Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Fludarabine Melphalan	treatment	Not Available	completed
NCT00309907	Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant	Etanercept Methylprednisolone Methylprednisolone hemisuccinate	treatment	2	completed
NCT01175785	Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies	Cyclophosphamide Cyclosporine Dilanubicel Fludarabine Mycophenolate mofetil	treatment	2	completed
NCT01588015	Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant	No drug interventions	supportive_care	1	completed
NCT01076270	Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Filgrastim Plerixafor	treatment	Not Available	terminated
NCT01231919	MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia	No drug interventions	treatment	1	completed
NCT00387426	Sunitinib in Treating Patients With Idiopathic Myelofibrosis	Sunitinib	treatment	2	terminated
NCT00860574	Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia	Fludarabine Methotrexate Tacrolimus Treosulfan	treatment	2	completed
NCT00054431	Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia	2'-Deoxycytidine Decitabine Imatinib	treatment	2	completed
NCT00012376	Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer	Bryostatin 1 Sargramostim	treatment	1	completed
NCT01053494	Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer	No drug interventions	supportive_care	Not Available	completed
NCT00795769	Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant	Ondansetron	supportive_care	2	completed
NCT01427881	Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies	Busulfan Cyclophosphamide Cyclosporine Fludarabine	treatment	2	completed
NCT01056614	Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies	Antilymphocyte immunoglobulin (horse) Antithymocyte immunoglobulin (rabbit) Busulfan Fludarabine Methotrexate Tacrolimus	treatment	2	completed
NCT01652014	Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies	Cyclophosphamide Fludarabine Mycophenolate mofetil Tacrolimus	treatment	2	withdrawn
NCT01789255	Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies	Cyclosporine Methotrexate Tacrolimus Vorinostat	supportive_care	2	completed
NCT00381550	3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia	Fludarabine Triapine	treatment	2	completed
NCT00301938	7-Hydroxystaurosporine and Perifosine in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia or High Risk Myelodysplastic Syndromes	7-Hydroxystaurosporine Perifosine	treatment	1	completed
NCT02782403	Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia	Axitinib Bosutinib	treatment	1	terminated
NCT01914484	Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia	Nilotinib Ruxolitinib	treatment	1 / 2	completed
NCT03934372	Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors	Ponatinib	treatment	1 / 2	recruiting
NCT01488253	Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell Transplants	Sirolimus Tacrolimus	prevention	2	terminated